# Inclisiran efficacy and evolving LDL cholesterol treatments > Live situation record from CLSTR: https://clstr.news/situations/inclisiran-efficacy-in-ldl-cholesterol-reduction > Updated: 2026-09-07T07:42:56.000Z. Sources: 9. Developments: 3. Research into the efficacy of inclisiran, a drug utilizing small interfering RNA (siRNA) technology to inhibit PCSK9 protein production, has demonstrated significant potential in reducing LDL cholesterol. An initial meta-analysis of nine randomized clinical trials involving over 6,300 participants found that inclisiran achieved an average LDL cholesterol reduction of approximately 49% compared to a placebo. The drug’s infrequent dosing schedule—requiring an injection only once every six months after initial doses—could improve patient compliance compared to daily statin regimens. Results from the Victorion-Challenge study, presented at the European Society of Cardiology (ESC) Congress in Munich, further established inclisiran’s efficacy in patients with high or very high cardiovascular risk from atherosclerotic cardiovascular disease (Ascvd). In this phase IV, randomized, open-label study, the inclisiran group saw a mean LDL-C reduction of 56.31% at day 150, compared to a 15.35% reduction in the bempedoic acid group. Notably, 78.2% of patients treated with inclisiran reached their target LDL-C levels, while only 20.3% of those on bempedoic acid achieved the same goal. Despite these differences in efficacy, the frequency of treatment-related adverse events was similar between the two groups, reported at 63.1% for inclisiran and 59.8% for bempedoic acid. The landscape for cholesterol management is expanding with the FDA approval of Lipfendra (enlicitide), the first oral PCSK9 inhibitor. Expected to be available by 2026, this medication provides an oral alternative to injectable treatments for high-risk adults. ## Claims - The Victorion-Challenge study was presented at the European Society of Cardiology (ESC) Congress in Munich. (corroborated by 4 sources) - The study is a randomized, open-label, phase IV trial. (corroborated by 4 sources) - The study compared inclisiran and bempedoic acid (BPA) in patients with high or very high cardiovascular risk. (corroborated by 4 sources) - The inclisiran group saw a mean LDL-C reduction of 56.31% at day 150. (corroborated by 4 sources) - The bempedoic acid group saw a mean LDL-C reduction of 15.35% at day 150. (corroborated by 4 sources) - 78.2% of patients treated with inclisiran reached the LDL-C target compared to 20.3% of those treated with bempedoic acid. (corroborated by 4 sources) - Adverse event frequency was comparable between groups (63.1% for inclisiran vs 59.8% for bempedoic acid). (corroborated by 4 sources) ## Timeline ### 2026-09-07: Cholesterol management: New study results and upcoming oral PCSK9 inhibitor Clinical studies show inclisiran significantly outperforms bempedoic acid in reducing LDL cholesterol, while the FDA-approved oral PCSK9 inhibitor Lipfendra is set to arrive by 2026. 2 sources. https://clstr.news/cluster/cholesterol-management-new-study-results-and-upcoming-oral-pcsk9-inhibitor ### 2026-09-03: Inclisiran outperforms bempedoic acid in LDL cholesterol reduction study The Victorion-Challenge study shows inclisiran significantly outperforms bempedoic acid in reducing LDL cholesterol for high-risk cardiovascular patients, with 78.2% reaching targets. 7 sources. https://clstr.news/cluster/inclisiran-outperforms-bempedoic-acid-in-ldl-cholesterol-reduction-study ### 2026-08-13: Inclisiran shows promise in reducing LDL cholesterol Inclisiran, an siRNA-based drug, reduces LDL cholesterol by approximately 49% through twice-yearly injections, offering a complementary treatment for high-risk patients. 2 sources. https://clstr.news/cluster/inclisiran-shows-promise-in-reducing-ldl-cholesterol --- Cite as: Inclisiran efficacy and evolving LDL cholesterol treatments. CLSTR, https://clstr.news/situations/inclisiran-efficacy-in-ldl-cholesterol-reduction